Development of vaccines for chikungunya fever

Jesse H. Erasmus, Shannan Rossi, Scott Weaver

Research output: Contribution to journalArticle

28 Scopus citations

Abstract

Chikungunya fever, an acute and often chronic arthralgic disease caused by the mosquito-borne chikungunya virus (CHIKV), has reemerged since 2004 to cause millions of cases. Because CHIKV exhibits limited antigenic diversity and is not known to be capable of reinfection, a vaccine could serve to both prevent disease and diminish human amplification during epidemic circulation. Here, we review the many promising vaccine platforms and candidates developed for CHIKV since the 1970s, including several in late preclinical or clinical development. We discuss the advantages and limitations of each, as well as the commercial and regulatory challenges to bringing a vaccine to market.

Original languageEnglish (US)
Pages (from-to)S488-S496
JournalJournal of Infectious Diseases
Volume214
DOIs
StatePublished - Dec 1 2016

Keywords

  • Alphavirus
  • Arthralgia
  • Chikungunya
  • Vaccine

ASJC Scopus subject areas

  • Immunology and Allergy
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Development of vaccines for chikungunya fever'. Together they form a unique fingerprint.

  • Cite this